tbuckley/cabot-search huggingface dataset:
Leaving Tiny, Unruptured Intracranial Aneurysms Untreated
Authors: S. Claiborne Johnston
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study
Authors: Andrea Penaloza, Caroline Soulié, Thomas Moumneh, Quentin Delmez, Alexandre Ghuysen, Dominique El Kouri, Christian Brice, Nicolas S Marjanovic, Jacques Bouget, Fares Moustafa, Albert Trinh-Duc, Catherine Le Gall, Lionel Imsaad, Jean-Marie Chrétien, Béatrice Gable, Philippe Girard, Olivier Sanchez, Jeannot Schmidt, Grégoire Le Gal, Guy Meyer, Nicolas Delvau, Pierre-Marie Roy
Journal: The Lancet Haematology (2017)
The “Promoting Resilience in Stress Management” (PRISM) intervention for adolescents and young adults: A pilot randomized controlled trial.
Authors: Abby R. Rosenberg, Miranda Bradford, Victoria Klein, Nicole Etsekson, Claire M Wharton, Michele Shaffer, Joyce P. Yi-Frazier
Journal: Journal of Clinical Oncology (2017)

176 Background: Adolescents and Young Adults (AYAs) with cancer are at risk for poor psychosocial outcomes, perhaps because they have yet to learn the skills needed to navigate the burdens of illness. We aimed to determine if a novel, brief, age-appropriate, skills-based intervention would improve psychosocial outcomes. Methods: “Promoting Resilience in Stress Management” (PRISM) is a manualized, brief intervention targeting stress management, goal-setting, cognitive reframing, and meaning-making. It consists of 4, 30-60 minute, in-person, 1:1 sessions plus a facilitated family-meeting. English-speaking AYAs (ages 12-25 years) with new or newly recurrent cancer were randomized to receive either PRISM or non-directive usual psychosocial care. Participants completed patient-reported outcome (PRO) surveys at the time of enrollment and 6 months later. We used mixed effects regression modeling to estimate associations between PRISM and the primary outcome (patient-reported resilience, measured by the Connor-Davidson Resilience Scale [CDRISC-10]) and secondary outcomes (health-related quality of life [PedsQL 4.0 Quality of Life Inventory], hope [Snyder Hope Scale], and psychological distress [Kessler-6 Psychological Distress Scale]) at 6 months. Results: N = 100 AYAs enrolled (78% of approached, n = 50 PRISM, n = 50 usual care) and 92 completed baseline responses (48 PRISM and 44 usual care). Of those who completed baseline, 73% were aged 13-17 years and 27% aged 18-25 years, and 43% were female. Attrition was similar in each arm and primarily due to medical complication and/or death; n = 36 (72%) PRISM and n = 38 (76%) usual care participants completed 6-month PROs. After adjusting for baseline scores, PRISM was associated with improvements in all instruments: Resilience (+2.3, 95% CI 0.7,4.0), quality of life (+6.3 (95% CI -0.8, 13.5), hope (+2.8, 95% CI 0.5, 5.1), and distress (-1.6, 95% CI -3.3, 0.0). Conclusions: A targeted intervention targeting skills for AYAs with cancer was effective in improving patient-centered outcomes. Clinical trial information: NCT02340884.
Are we addressing relevant determinants of smoking cessation?
Authors: Pasquale Caponnetto, Riccardo Polosa
Journal: European Respiratory Journal (2017)

The identification of factors that may predict success in smoking cessation efforts is highly desirable as this could help to match smokers with a strategy more likely to help them quit, as well as helping to optimise healthcare resources and refine state-funded tobacco policies. Although several factors have been extensively investigated, both in aided and unaided smoking cessation, no consistent determinants of smoking cessation have been identified [1]. Predictors recorded at baseline may not be representative of the dynamic psychophysical changes in quitting <http://ow.ly/2pk830fFx8x>
Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)
Authors: K. Miller, L. S. Rosen, S. Modi, B. Schneider, J. Roy, L. Chap, M. Paulsen, K. Kersey, A. Hannah, C. Hudis
Journal: Journal of Clinical Oncology (2007)

1115 Background: Alvespimycin (A) inhibits the activity of Hsp90, resulting in degradation of client proteins, such as the HER2 receptor. In vivo, Hsp90 inhibition induces rapid degradation of HER2 with loss of pAKT, cyclin D2 and tumor growth inhibition. Methods: Pts receive standard weekly doses of T followed by A in escalating doses via IV doses over 1 hr. Define the recommended dose (RP2D), toxicity and signs of activity of T+A in pts with solid tumors. PK: assessed after the 1 st and 4 th infusion. PBLs: purified to investigate changes in intracellular signaling proteins by immunoblot. The RP2D will produce DLT in no more than 1/6 evaluable pts. Results: 21 pts enrolled in 3 cohorts (60, 80 and 100 mg/m 2 ). Median age 53 yrs, range 31–75; median KPS 90; prior regimens not including hormonal therapy: median 6, range 1–13; prior T-regimens for MBC pts: median 3, range 0–9. Diagnoses: HER2+ MBC (n=18), ovarian (n=3). DLT was observed at the highest dose, consisting of 1 pt with hypoxia and ↓LVEF; an additional pt at this dose had Grade 3 ↑AST, however ↑hepatic metastases and ascites were observed. Drug-related toxicity: diarrhea (60%), fatigue, headache (both 45%), nausea, arthralgias (both 40%), dry eye and pain in extremity (both 25%); all Grade 1–2 severity except 1 episode of Gr3 fatigue and Gr3 diarrhea. PK (n=18): t½ 17.7 hr (32%CV); Clearance 18.1 L/hr (46%CV); Vz 438L (42%CV); no change upon weekly dosing. AUC inf /C max (100 mg/m 2 ): 14268 ng*hr/mL (60%CV) and 2233 ng/mL (23.5%CV). HER2+ MBC activity: 1 pt (13 prior regimens; 3x T and 1x lapatanib) with evaluable disease showed near complete resolution of lung metastases by CT/PET with significant improvement in dyspnea; 3 pts with HER2+ MBC with SD (4, 5 and 7+ months). Ovarian CA activity: 1 pt (HER2 unknown; 13 prior regimens; 11+ months on-study) with evaluable disease showed near complete resolution of ascites and pleural effusion at end of Cycle 2 with ↓83% CA125. Dose-dependent increase in Hsp70 in PBLs; at 80 and 100 mg/m 2 , Hsp70 induction was maintained prior to successive weekly doses. Conclusions: Combination of T+A has signs of activity in H-refractory HER2+ MBC and refractory ovarian cancer. Definition of RP2D dose is pending. Toxicity has been manageable. No significant financial relationships to disclose.
Abstract 15730: Failure-to-Prevent Drives Variation in Mortality After Pediatric Cardiac Arrest More So Than Failure-to-Rescue
Authors: Michael Gaies, Jeffrey Alten, Darren Klugman, David Cooper, Sara Pasquali, Wenying Zhang, Amir Ghaferi, Justin Dimick, Mousumi Banerjee, Brahmajee Nallamothu
Journal: Circulation (2017)

Introduction: For most complications, previous literature suggests that failure-to-rescue (FTR) may be a more important driver of mortality than strategies for prevention in hospitalized patients. ...
NHS England’s handling of 102 000 lost medical records is “unacceptable,” say MPs
Authors: Abi Rimmer
Journal: BMJ (2017)

NHS England has “given up” trying to find out whether patients have been harmed by the loss of 102 000 items of lost medical correspondence, MPs have said.

In a report on the handling of lost clinical correspondence, the House of Commons Public Accounts Committee said that NHS England’s decision not to follow up on the correspondence was unacceptable.

In March 2016 NHS Shared Business Services, an agency co-owned by the Department of Health and the IT company Sopra Steria, revealed that 709 000 items of medical correspondence had been lost.1 This included test results, such as cervical screening results, and child protection notes. In …
MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization
Authors: Christopher J Walker, Craig M Rush, Paola Dama, Matthew J O’Hern, Casey M Cosgrove, Jessica L Gillespie, Roman A Zingarelli, Blair Smith, Maggie E Stein, David G Mutch, Reena Shakya, Chia-Wen Chang, Karuppaiyah Selvendiran, Jonathan W Song, David E Cohn, Paul J Goodfellow
Journal: JNCI Journal of the National Cancer Institute (2017)

BackgroundGenomic studies have revealed that multiple genes are mutated at varying frequency in endometrial cancer (EC); however, the relevance of many of these mutations is poorly understood. An EC-specific recurrent mutation in the MAX transcription factor p.His28Arg was recently discovered. We sought to assess the functional consequences of this hotspot mutation and determine its association with cancer-relevant phenotypes.
S-1 plus cisplatin combination therapy in patients with urachal carcinoma: A retrospective study
Authors: R. Oki, C. Kondoh, Y. Miura, Y. Ozaki, Y. Tanabe, K. Sakaguchi, K. Kurosawa, S. Urakami, T. Okaneya, T. Takano
Journal: Annals of Oncology (2017)
Uncertainty about future payoffs makes impatience rational
Authors: James Holland Jones
Journal: Behavioral and Brain Sciences (2017)

Abstract Uncertainty (i.e., variable payoffs with unknown probabilities) brings together a number of features of the authors' argument. It leads to present bias, even for completely rational agents with time-consistent preferences. As an evolutionary product of Pleistocene climate instability, humans possess broad adaptations to environmental uncertainty, giving rise to key features of the behavioral constellation of deprivation (BCD).
Ghost of chest drain past
Authors: Freddy Frost, James Hare, John Holemans, Martin Walshaw
Journal: Thorax (2017)

A 20-year-old woman with recurrent left-sided pneumothoraces underwent video-assisted thoracoscopic pleurectomy and wedge resection of a left apical bulla. Medical history included ABCA3 pulmonary surfactant dysfunction and subsequent interstitial lung disease with diffuse ground glass changes suggestive of a desquamative interstitial pneumonitis (DIP). She was a lifelong non-smoker. Spirometry revealed forced vital capacity 0.97 L, 32% predicted and carbon monoxide transfer factor (TLCO) 27% predicted. The operation was uneventful but there was a persistent postoperative air leak requiring prolonged pleural drainage but no other intervention. …
Drug Repositioning Meets Precision in Glioblastoma
Authors: Wolfgang Wick, Tobias Kessler
Journal: Clinical Cancer Research (2017)

Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue, and revisiting drugs with a focus on brain tumor penetration may yield surprises. Clin Cancer Res; 24(2); 256-8. ©2017 AACRSee related article by Byron et al., p. 295.
High mobility group protein B1 controls liver cancer initiation through yes‐associated protein ‐dependent aerobic glycolysis
Authors: Ruochan Chen, Shan Zhu, Xue‐Gong Fan, Haichao Wang, Michael T. Lotze, Herbert J. Zeh, Timothy R. Billiar, Rui Kang, Daolin Tang
Journal: Hepatology (2017)

Emerging studies have suggested that the Hippo pathway is involved in the tumorigenesis of hepatocellular carcinoma (HCC). However, the key regulator of the Hippo pathway in liver tumor metabolic reprogramming remains elusive. Here, we provide evidence that high mobility group box 1 (HMGB1), a chromosomal protein, plays a role in the regulation of the Hippo pathway during liver tumorigenesis. Cre/loxP recombination-mediated HMGB1 depletion in hepatocytes blocks diethylnitrosamine-induced liver cancer initiation in mice, whereas short hairpin RNA-mediated gene silencing of HMGB1 inhibits HCC cell proliferation. Mechanistically, the binding of HMGB1 to GA-binding protein alpha promotes the expression of yes-associated protein (YAP), a major downstream effector of the Hippo pathway that contributes to liver tumorigenesis by inducing hypoxia-inducible factor 1α (HIF1α)-dependent aerobic glycolysis. Like wild-type YAP-complementary DNA, YAP-5SA-S94A can restore HIF1α DNA binding activity, glycolysis-associated gene expression, and HIF1α-YAP complex formation in YAP-knockdown HCC cell lines. In contrast, verteporfin, a reagent targeting the interface between YAP and TEA domain transcription factor, has the ability to block YAP-HIF1α complex formation. Notably, genetic or pharmacologic inhibition of the HMGB1-YAP-HIF1α pathway confers protection against excessive glycolysis and tumor growth in mice.
Relevance of rapid geriatric assessment for elderly patients with newly diagnosed malignancy.
Authors: Hina Niranjan Mehta, Rania Farhat, Sravanthi Ravulapati, Yifan Tu
Journal: Journal of Clinical Oncology (2017)

115 Background: The elderly population is the fastest growing segment of the US population, and it is widely affected by cancer and its related sequelae. At St. Louis University (SLU), a simple Rapid Geriatric Assessment (RGA) was developed based on the SLU Mental Status Exam (SLUMS). The RGA includes screening for frailty, sarcopenia, nutrition, and cognition. In this pilot study, we used RGA to assess geriatric patients with newly diagnosed malignancy prior to cancer therapy and its ability to improve outcomes in oncology patients. Methods: Elderly patients (aged 65 and above) with newly diagnosed malignancy completed the RGA either inpatient or outpatient at SLU. A retrospective chart review was done to collect patient's demographics, type of malignancy, number of hospitalizations since diagnosis and referral to palliative care over a 6 month period. Relationship between tolerability and RGA subscores were assessed using general linear models, Kaplan-Meier survival analysis and Chi-square testing. Results: Twenty six patients (mean age 76 [65-90]) were included from December 2015 to 2016 of which 9 were male (n = 35) and 17 female (n = 65). 19 patients (73%) were inpatient, 7 (27%) were outpatient and 13 patients (50%) received chemotherapy. Using the Mann-Whitney U test, no significant difference was seen between RGA subscores (FRAIL p = 1; SNAQ p = 0.69; SARC-F p = 0.71; RCS p = 1) in patients receiving versus not receiving chemotherapy. There was no significant difference in overall survival (OS) over a 20 month period based on chemotherapy status (p = 0.39). In our study, 62% of patients (n = 16) were referred to palliative care and noted to have a significant better OS (p = 0.04). Conclusions: The RGA is a self-explanatory tool that can be used in geriatric oncology patients and it can bedone in 10 minutes. In this pilot study, we used this tool in a small number of patients. We plan to perform a prospective study to evaluate the RGA comparing to ECOG-performance status in geriatric patients prior to standard cancer therapies. Improvement of overall survival with incorporation of palliative care in oncology patients is reaffirmed in our study.
Coronary Computed Tomography–Based Fractional Flow Reserve—Reply
Authors: Christopher M. Cook, Ricardo Petraco, Justin E. Davies
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract 16038: Poor Demonstration and Knowledge of AED Electrode Placement by Certified and Experienced BLS/AED Instructors
Authors: Mathilde Stærk, Lauge Vammen, Camilla Hansen, Kristian Krogh, Bo Løfgren
Journal: Circulation (2017)

Introduction: Use of an automated external defibrillator (AED) improves survival. Incorrect AED electrode placement may affect defibrillation success and survival. During courses in basic life supp...
Final analysis of phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
Authors: A. Tanaka, A. Tamiya, M. Tamiya, S. Morita, T. Shiroyama, N. Saijo, S. Minomo, T. Tsuji, N. Takeuchi, N. Omachi, N. Morishita, H. Suzuki, N. Okamoto, K. Okishio, T. Hirashima, S. Atagi
Journal: Annals of Oncology (2017)
P2.07-003 Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Authors: H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, T. Funazo, Y. Yasuda, T. Hirai
Journal: Journal of Thoracic Oncology (2017)
DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development
Authors: Judith Kraiczy, Komal M Nayak, Kate J Howell, Alexander Ross, Jessica Forbester, Camilla Salvestrini, Roxana Mustata, Sally Perkins, Amanda Andersson-Rolf, Esther Leenen, Anke Liebert, Ludovic Vallier, Philip C Rosenstiel, Oliver Stegle, Gordon Dougan, Robert Heuschkel, Bon-Kyoung Koo, Matthias Zilbauer
Journal: Gut (2017)

Objective Human intestinal epithelial organoids (IEOs) are increasingly being recognised as a highly promising translational research tool. However, our understanding of their epigenetic molecular characteristics and behaviour in culture remains limited. Design We performed genome-wide DNA methylation and transcriptomic profiling of human IEOs derived from paediatric/adult and fetal small and large bowel as well as matching purified human gut epithelium. Furthermore, organoids were subjected to in vitro differentiation and genome editing using CRISPR/Cas9 technology. Results We discovered stable epigenetic signatures which define regional differences in gut epithelial function, including induction of segment-specific genes during cellular differentiation. Established DNA methylation profiles were independent of cellular environment since organoids retained their regional DNA methylation over prolonged culture periods. In contrast to paediatric and adult organoids, fetal gut-derived organoids showed distinct dynamic changes of DNA methylation and gene expression in culture, indicative of an in vitro maturation. By applying CRISPR/Cas9 genome editing to fetal organoids, we demonstrate that this process is partly regulated by TET1, an enzyme involved in the DNA demethylation process. Lastly, generating IEOs from a child diagnosed with gastric heterotopia revealed persistent and distinct disease-associated DNA methylation differences, highlighting the use of organoids as disease-specific research models. Conclusions Our study demonstrates striking similarities of epigenetic signatures in mucosa-derived IEOs with matching primary epithelium. Moreover, these results suggest that intestinal stem cell-intrinsic DNA methylation patterns establish and maintain regional gut specification and are involved in early epithelial development and disease.
Incidental Case of Relapsing Polychondritis Detected by 18F-FDG PET/CT
Authors: Hayato Kaida, Kazunari Ishii, Soichiro Hanada, Yuji Tohda, Takamichi Murakami
Journal: Clinical Nuclear Medicine (2017)

A 78-year-old man had fever, persistent wheezing, and serum C-reactive protein elevation. Malignant lymphoma was suspected because of mediastinal lymph nodes swelling on CT and soluble interleukin 2 receptor elevation. Symmetric F-FDG uptake in the tracheobronchial tree and bilateral auricles was observed on PET/CT. He was finally diagnosed as having relapsing polychondritis by auricular cartilage biopsy. F-FDG PET/CT may have crucial role in evaluating the extent of inflammation and deciding the biopsy site of relapsing polychondritis.
A retrospective review of patients with hematological malignancy referred to an inpatient palliative care service in a tertiary hospital.
Authors: Yee Choon Meng, Mervyn Yong Hwang Koh, Zi Yan Chiam, Jun Jun Zhang, Yin Mei, Allyn Hum
Journal: Journal of Clinical Oncology (2017)

117 Background: Patients with hematological malignancies are referred to palliative care service later and less often than patients with solid organ tumor. However, there are no data in Singapore, on the referral pattern among patients with hematological malignancy. The objective of the study is to identify the characteristics and outcomes of patients with hematological malignancy referred to an In-patient Palliative Care Service (PCS). Methods: We performed a retrospective review of all patients with hematological malignancies referred to the in-patient PCS from December 2015 to December 2016. Basic demographics and outcomes of patients’ admission were collected as per protocol. Results: 53 patients were included in the study. 27 (50.9%) patients were male, 49 (92.5%) were ≥60 years old, 20 (37.7%) were receiving cancer treatment at the point of referral, and 24 (45.3%) had Palliative Performance Scale (PPS) ≤ 40%. The most common hematological diagnosis was lymphoma (N = 26, 49.1%). The top 3 reasons for referral were symptom management (N = 44; 83%), advance disease (N = 24; 45.3% and end-of-life discussion (N = 15, 28.3%). Among 44 patients referred for symptom control, 18 (40.9%) had pain, 12 (27.3%) had dyspnoea, 8 (18.2%) had confusion and 6 (13.6%) had fatigue or drowsiness. 30 patients (56.6%) died during the admission. Among 30 patients who died, the mean time from referral to death was 9.8 days; 16 (53.3%) died within 1 week from referral, 9 (30%) died between 1-4 weeks from referral and 5 (16.7%) died beyond 4 weeks after referral.5 patients (9.4%) had Advance Care Planning completed. Conclusions: Our review showed that patients with hematological malignancies are referred late in their disease trajectory and have high Palliative Care needs. Hence, collaborative effort to facilitate timely referral of patients with hematological malignancy to PCS will optimize end-of-life care.